Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2010

Open Access 01-12-2010 | Short report

Mutations at positions 186 and 194 in the HA gene of the 2009 H1N1 pandemic influenza virus improve replication in cell culture and eggs

Authors: Pirada Suphaphiphat, Michael Franti, Armin Hekele, Anders Lilja, Terika Spencer, Ethan Settembre, Gene Palmer, Stefania Crotta, Annunziata B Tuccino, Bjoern Keiner, Heidi Trusheim, Kara Balabanis, Melissa Sackal, Mithra Rothfeder, Christian W Mandl, Philip R Dormitzer, Peter W Mason

Published in: Virology Journal | Issue 1/2010

Login to get access

Abstract

Obtaining suitable seed viruses for influenza vaccines poses a challenge for public health authorities and manufacturers. We used reverse genetics to generate vaccine seed-compatible viruses from the 2009 pandemic swine-origin influenza virus. Comparison of viruses recovered with variations in residues 186 and 194 (based on the H3 numbering system) of the viral hemagglutinin showed that these viruses differed with respect to their ability to grow in eggs and cultured cells. Thus, we have demonstrated that molecular cloning of members of a quasispecies can help in selection of seed viruses for vaccine manufacture.
Appendix
Available only for authorised users
Literature
1.
Update: infections with a swine-origin influenza A (H1N1) virus--United States and other countries, April 28, 2009 MMWR Morb Mortal Wkly Rep 2009, 58: 431-433.
2.
Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, Lochindarat S, Nguyen TK, Nguyen TH, Tran TH, et al.: Avian influenza A (H5N1) infection in humans. N Engl J Med 2005, 353: 1374-1385. 10.1056/NEJMra052211PubMedCrossRef
3.
Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM: Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360: 2605-2615. 10.1056/NEJMoa0903810PubMedCrossRef
4.
Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez DR, Donis R, Hoffmann E, et al.: Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 1999, 96: 9345-9350. 10.1073/pnas.96.16.9345PubMedPubMedCentralCrossRef
5.
Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A: Rescue of influenza A virus from recombinant DNA. J Virol 1999, 73: 9679-9682.PubMedPubMedCentral
6.
Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova EA, McClain-Moss LR, Peiris JS, Rehg JE, Tuomanen EI, Webster RG: Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004, 363: 1099-1103. 10.1016/S0140-6736(04)15892-3PubMedCrossRef
7.
Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG: A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 2000, 97: 6108-6113. 10.1073/pnas.100133697PubMedPubMedCentralCrossRef
8.
Hoffmann E, Krauss S, Perez D, Webby R, Webster RG: Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 2002, 20: 3165-3170. 10.1016/S0264-410X(02)00268-2PubMedCrossRef
9.
Suphaphiphat P, Keiner B, Trusheim H, Crotta S, Tuccino AB, Zhang P, Dormitzer PR, Mason PW, Franti M: Human RNA Polymerase I-Driven Reverse Genetics for Influenza A Virus in Canine Cells. J Virol 2010, 84: 3721-3725. 10.1128/JVI.01925-09PubMedPubMedCentralCrossRef
10.
Bottcher E, Matrosovich T, Beyerle M, Klenk HD, Garten W, Matrosovich M: Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J Virol 2006, 80: 9896-9898. 10.1128/JVI.01118-06PubMedPubMedCentralCrossRef
11.
Gamblin SJ, Haire LF, Russell RJ, Stevens DJ, Xiao B, Ha Y, Vasisht N, Steinhauer DA, Daniels RS, Elliot A, et al.: The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 2004, 303: 1838-1842. 10.1126/science.1093155PubMedCrossRef
12.
Kilbourne ED, Taylor AH, Whitaker CW, Sahai R, Caton AJ: Hemagglutinin polymorphism as the basis for low- and high-yield phenotypes of swine influenza virus. Proc Natl Acad Sci USA 1988, 85: 7782-7785. 10.1073/pnas.85.20.7782PubMedPubMedCentralCrossRef
13.
Bush RM, Fitch WM, Bender CA, Cox NJ: Positive selection on the H3 hemagglutinin gene of human influenza virus A. Mol Biol Evol 1999, 16: 1457-1465.PubMedCrossRef
14.
Gubareva LV, Wood JM, Meyer WJ, Katz JM, Robertson JS, Major D, Webster RG: Codominant mixtures of viruses in reference strains of influenza virus due to host cell variation. Virology 1994, 199: 89-97. 10.1006/viro.1994.1100PubMedCrossRef
15.
Pyhala R, Ikonen N, Haanpaa M, Kinnunen L: HA1 domain of influenza A (H3N2) viruses in Finland in 1989-1995: evolution, egg-adaptation and relationship to vaccine strains. Arch Virol 1996, 141: 1033-1046. 10.1007/BF01718607PubMedCrossRef
16.
Glaser L, Stevens J, Zamarin D, Wilson IA, Garcia-Sastre A, Tumpey TM, Basler CF, Taubenberger JK, Palese P: A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol 2005, 79: 11533-11536. 10.1128/JVI.79.17.11533-11536.2005PubMedPubMedCentralCrossRef
17.
Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, et al.: Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans. Science 2009, 325: 197-201. 10.1126/science.1176225PubMedPubMedCentralCrossRef
18.
Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, Ma SK, Cheung CL, Raghwani J, Bhatt S, et al.: Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009, 459: 1122-1125. 10.1038/nature08182PubMedCrossRef
19.
Chen Z, Wang W, Zhou H, Suguitan AL Jr, Shambaugh C, Kim L, Zhao J, Kemble G, Jin H: Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol 2010, 84: 44-51. 10.1128/JVI.02106-09PubMedPubMedCentralCrossRef
20.
Childs RA, Palma AS, Wharton S, Matrosovich T, Liu Y, Chai W, Campanero-Rhodes MA, Zhang Y, Eickmann M, Kiso M, et al.: Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray. Nat Biotechnol 2009, 27: 797-799. 10.1038/nbt0909-797PubMedPubMedCentralCrossRef
21.
Okuno Y, Tanaka K, Baba K, Maeda A, Kunita N, Ueda S: Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system. J Clin Microbiol 1990, 28: 1308-1313.PubMedPubMedCentral
22.
Killian ML: Hemagglutination assay for the avian influenza virus. In Avian Influenza Virus. Volume 436. Edited by: Spackman E. Totowa. NJ: Humana Press; 2008:47-52. Methods in Molecualr Biology full_textCrossRef
23.
Jones TA, Zou JY, Cowan SW, Kjeldgaard M: Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 1991,47(Pt 2):110-119. 10.1107/S0108767390010224PubMedCrossRef
24.
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE: UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 2004, 25: 1605-1612. 10.1002/jcc.20084PubMedCrossRef
25.
Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine MMWR Morb Mortal Wkly Rep 2009, 58: 521-524.
Metadata
Title
Mutations at positions 186 and 194 in the HA gene of the 2009 H1N1 pandemic influenza virus improve replication in cell culture and eggs
Authors
Pirada Suphaphiphat
Michael Franti
Armin Hekele
Anders Lilja
Terika Spencer
Ethan Settembre
Gene Palmer
Stefania Crotta
Annunziata B Tuccino
Bjoern Keiner
Heidi Trusheim
Kara Balabanis
Melissa Sackal
Mithra Rothfeder
Christian W Mandl
Philip R Dormitzer
Peter W Mason
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2010
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-7-157

Other articles of this Issue 1/2010

Virology Journal 1/2010 Go to the issue

Research

Detection of swine transmissible gastroenteritis coronavirus using loop-mediated isothermal amplification

Research

Evolution of Dengue Virus Type 3 Genotype III in Venezuela: Diversification, Rates and Population Dynamics

Editorial

Bacteriophage T4 and its relatives

Research

Profiles of cytokine and chemokine gene expression in human pulmonary epithelial cells induced by human and avian influenza viruses

Research

Phylogenetic analyses of the polyprotein coding sequences of serotype O foot-and-mouth disease viruses in East Africa: evidence for interserotypic recombination

Research

Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits